Centers for Disease Control and Prevention (CDC) Cigarette smoking among adults–United States, 1997. MMWR Morb Mortal Wkly Rep.
Centers for Disease Control and Prevention (CDC) Cigarette smoking among adults—United States, 2007. MMWR Morb Mortal Wkly Rep.
World Health Organization WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER Package. 2008; Geneva, Switzerland World Health Organization
Henningfield JE, Miyasato K, Jasinski DR. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther.
Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature.
1998;3916663:173-177. [CrossRef] [PubMed]
Burgess JK, Oliver BG, Poniris MH, et al. A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro. J Allergy Clin Immunol.
2006;1183:649-657. [CrossRef] [PubMed]
Lerman CE, Schnoll RA, Munafò MR. Genetics and smoking cessation improving outcomes in smokers at risk. Am J Prev Med.
2007;336suppl:S398-S405. [CrossRef] [PubMed]
Shiffman S. Tobacco “chippers”—individual differences in tobacco dependence. Psychopharmacology (Berl).
1989;974:539-547. [CrossRef] [PubMed]
American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 1994;4th ed Washington, D.C. American Psychiatric Association
US Department of Health and Human Services The Health Benefits of Smoking Cessation. A Report of the Surgeon General. 1990; Washington, DC US Dept Health and Human Services:90-8416 CDC publication.
Centers for Disease Control and Prevention (CDC) Annual smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 1997-2001. MMWR Morb Mortal Wkly Rep.
O’Hara P, Connett JE, Lee WW, Nides M, Murray R, Wise R. Early and late weight gain following smoking cessation in the Lung Health Study. Am J Epidemiol.
1998;1489:821-830. [CrossRef] [PubMed]
Parsons AC, Shraim M, Inglis J, Aveyard P, Hajek P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2009;1:CD006219
Turner L, Mermelstein R, Flay B. Individual and contextual influences on adolescent smoking. Ann N Y Acad Sci.
2004;1021:175-197. [CrossRef] [PubMed]
Farrelly MC, Pechacek TF, Thomas KY, Nelson D. The impact of tobacco control programs on adult smoking. Am J Public Health.
2008;982:304-309. [CrossRef] [PubMed]
Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. More good news on teen smoking: rates at or near record lows. http://www.monitoringthefuture.org
. Accessed October 15, 2009.
Hines D, Fretz AC, Nollen NL. Regular and occasional smoking by college students: personality attributions of smokers and nonsmokers. Psychol Rep.
1998;833 Pt 2:1299-1306. [PubMed]
Clark EM, Klesges RC, Neimeyer RA. Attributions about sexual behavior, attractiveness and health as a function of subjects’ and targets’ sex and smoking status. Basic Appl Soc Psych.
Cooper WH, Kohn PM. The social image of the young female smoker. Br J Addict.
1989;848:935-941. [CrossRef] [PubMed]
Dermer ML, Jacobsen E. Some potential negative social consequences of cigarette smoking: marketing research in reverse. J Appl Soc Psychol.
Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2004;4:CD000165
Balas EA, Weingarten S, Garb CT, Blumenthal D, Boren SA, Brown GD. Improving preventive care by prompting physicians. Arch Intern Med.
2000;1603:301-308. [CrossRef] [PubMed]
Nicotrol vs Nicotine Nasal Spray [product information]. 2005; Morris Plains, NJ Pfizer Consumer Healthcare
Hajek P, McRobbie H, Gillison F. Dependence potential of nicotine replacement treatments: effects of product type, patient characteristics, and cost to user. Prev Med.
2007;443:230-234. [CrossRef] [PubMed]
Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. 2008; Rockville, MD US Dept of Health and Human Services
Rigotti NA, Munafo MR, Murphy MF, Stead LF. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2003;1:CD001837
Daughton DM, Heatley SA, Prendergast JJ, et al. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo-controlled, double-blind study. Arch Intern Med.
1991;1514:749-752. [CrossRef] [PubMed]
Smith SS, Jorenby DE, Leischow SJ, et al. Targeting smokers at increased risk for relapse: treating women and those with a history of depression. Nicotine Tob Res.
2003;51:99-109. [CrossRef] [PubMed]
Burkhalter JE, Springer CM, Chhabra R, Ostroff JS, Rapkin BD. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. Nicotine Tob Res.
2005;74:511-522. [CrossRef] [PubMed]
Arnsten JH, Reid K, Bierer M, Rigotti N. Smoking behavior and interest in quitting among homeless smokers. Addict Behav.
2004;296:1155-1161. [CrossRef] [PubMed]
Hughes JR, Kalman D. Do smokers with alcohol problems have more difficulty quitting? Drug Alcohol Depend.
2006;822:91-102. [CrossRef] [PubMed]
DiClemente CC, Prochaska JO, Fairhurst SK, Velicer WF, Velasquez MM, Rossi JS. The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change. J Consult Clin Psychol.
1991;592:295-304. [CrossRef] [PubMed]
Fiore MC. Treating tobacco use and dependence: an introduction to the US Public Health Service clinical practice guideline. Respir Care.
White AR, Rampes H, Ernst E. Acupuncture for smoking cessation. Cochrane Database Syst Rev. 2002;2:CD000009
Abbot NC, Stead LF, White AR, Barnes J, Ernst E. Hypnotherapy for smoking cessation. Cochrane Database Syst Rev. 2000;2:CD001008
McPhillips-Tangum C, Bocchino C, Carreon R, et al. Addressing tobacco in managed care: results of the 2002 survey. Prev Chronic Dis.
Fiore M, Bailey W, Cohen S, et al. Treating Tobacco Use and Dependence. 2000; Rockville, MD US Department of Health and Human Services
Theobald M, Jaén CR. An update on tobacco cessation reimbursement. Fam Pract Manag.
2006;135:75-76 78.. [PubMed]
Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;3:CD000146
Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control.
2006;154:280-285. [CrossRef] [PubMed]
Croghan IT, Hurt RD, Dakhil SR, et al. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc.
Steinberg MB, Foulds J, Richardson DL, Burke MV, Shah P. Pharmacotherapy and smoking cessation at a tobacco dependence clinic. Prev Med.
2006;422:114-119. [CrossRef] [PubMed]
Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol.
2007;274:380-386. [CrossRef] [PubMed]
Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med.
1999;3409:685-691. [CrossRef] [PubMed]
Steinberg MB, Greenhaus S, Schmelzer AC, et al. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med.
Kozlowski LT, Giovino GA, Edwards B, et al. Advice on using over-the-counter nicotine replacement therapy-patch, gum, or lozenge-to quit smoking. Addict Behav.
2007;3210:2140-2150. [CrossRef] [PubMed]
Henningfield JE, Radzius A, Cooper TM, Clayton RR. Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum. JAMA.
1990;26412:1560-1564. [CrossRef] [PubMed]
Commit Oral Lozenge, Nicotine Polacrilex Oral Lozenge [product information]. 2003; Pittsburgh, PA GlaxoSmithKline
Nicorette Gum, Nicotine Polacrilex Gum [product information]. 2005; Moon Township, PA GlaxoSmithKline
Hughes JR, Gust SW, Keenan R, Fenwick JW, Skoog K, Higgins ST. Long-term use of nicotine vs placebo gum. Arch Intern Med.
1991;15110:1993-1998. [CrossRef] [PubMed]
Nicotrol Inhalation Solution, Nicotine Inhalation Solution [product information]. 2005; Morris Plains, NJ Pfizer
Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol.
1997;297:1422-1431. [CrossRef] [PubMed]
Ford CL, Zlabek JA. Nicotine replacement therapy and cardiovascular disease. Mayo Clin Proc.
2005;805:652-656. [CrossRef] [PubMed]
Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med.
1996;33524:1792-1798. [CrossRef] [PubMed]
Mahmarian JJ, Moyé LA, Nasser GA, et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol.
1997;301:125-130. [CrossRef] [PubMed]
Working Group for the Study of Transdermal Nicotine in Patients With Coronary Artery Disease Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med.
1994;1549:989-995. [CrossRef] [PubMed]
Coleman T, Thornton J, Britton J, et al. Protocol for the smoking, nicotine and pregnancy (SNAP) trial: double-blind, placebo-randomised, controlled trial of nicotine replacement therapy in pregnancy. BMC Health Serv Res.
2007;7:2. [CrossRef] [PubMed]
Dempsey DA, Benowitz NL. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf.
2001;244:277-322. [CrossRef] [PubMed]
Wisborg K, Henriksen TB, Jespersen LB, Secher NJ. Nicotine patches for pregnant smokers: a randomized controlled study. Obstet Gynecol.
2000;966:967-971. [CrossRef] [PubMed]
Hegaard HK, Kjaergaard H, Møller LF, Wachmann H, Ottesen B. Multimodal intervention raises smoking cessation rate during pregnancy. Acta Obstet Gynecol Scand.
2003;829:813-819. [CrossRef] [PubMed]
Zyban Bupropion Hydrochloride Sustained-Release Tablets [product information]. 2007; Research Triangle Park, NC GlaxoSmithKline
Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;1:CD000031
Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med.
1997;33717:1195-1202. [CrossRef] [PubMed]
Swan GE, McAfee T, Curry SJ, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med.
2003;16319:2337-2344. [CrossRef] [PubMed]
Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med.
Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med.
2006;16615:1553-1559. [CrossRef] [PubMed]
Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem.
2005;4810:3474-3477. [CrossRef] [PubMed]
Olausson P, Jentsch JD, Taylor JR. Repeated nicotine exposure enhances responding with conditioned reinforcement. Psychopharmacology (Berl).
2004;1731-2:98-104. [CrossRef] [PubMed]
Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2007;1:CD006103
Chantix Varenicline Tablets [product information]. 2008; New York Pfizer
Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2004;3:CD000058
Cornuz J, Gilbert A, Pinget C, et al. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tob Control.
2006;153:152-159. [CrossRef] [PubMed]
Bolin K, Mörk AC, Willers S, Lindgren B. Varenicline as compared to bupropion in smoking-cessation therapy—cost-utility results for Sweden 2003. Respir Med.
2008;1025:699-710. [CrossRef] [PubMed]
Stratton K, Shetty P, Wallace R, Bondurant S. Committee to Assess the Science Base for Tobacco Harm Reduction, Board on Health Promotion and Disease Prevention. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. 2001; Washington, D.C. National Academy Press
Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev. 2007;:CD005353
Hatsukami DK, Rennard S, Jorenby D, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther.
2005;785:456-467. [CrossRef] [PubMed]